Andere Sprachen MaxCyte, Inc. Nasdaq

Aktien

A2AGVE

US57777K1060

MXCT

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 27.06.2024			% 5 Tage	% 1. Jan.
4 ^USD	+0.50%		-3.85%	-14.89%

11.06.	MaxCyte CEO Maher Masoud kauft 100.000 Aktien	AN
11.06.	Maxcyte-Insider kaufte Aktien im Wert von $489.066, laut einer aktuellen SEC-Anmeldung	MT

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Porton Advanced introduces the MaxCyte ExPERT GTx Flow Electroporation instrument, continuing to provide customers with end-to-end cell and gene therapy CRO and CDMO services	26.06.
MaxCyte, Inc. - Grant of Options and Restricted Stock Units	17.06.
MaxCyte, Inc. - Results of AGM	13.06.
MaxCyte, Inc. - PDMR Dealing	12.06.
MaxCyte CEO Maher Masoud buys 100,000 shares	11.06.
Maxcyte Insider Bought Shares Worth $489,066, According to a Recent SEC Filing	11.06.
MaxCyte : Participation in Upcoming Investor Conference	29.05.
MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference	29.05.
MaxCyte inks deal with Legend Biotech for tech supply	22.05.
MaxCyte Signs License Deal With Legend Biotech for Cell Therapy Program	22.05.
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development	22.05.
MaxCyte, Inc. Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development	22.05.
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance	09.05.
MaxCyte announces filing of Form 10-Q for the quarterly period ended March 31, 2024	09.05.
MaxCyte Shares Rise Sharply After Q1 Results Beat	08.05.
MaxCyte shares rise amid double-digit revenue increase	08.05.
Earnings Flash (MXCT.L) MAXCYTE Posts Q1 Revenue $11.3M	08.05.
Earnings Flash (MXCT.L) MAXCYTE Reports Q1 Loss $-0.09	08.05.
MaxCyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07.05.
Earnings Flash (MXCT) MAXCYTE Reports Q1 Revenue $11.3M, vs. Street Est of $7.5M	07.05.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen MaxCyte, Inc. Nasdaq

Aktien

A2AGVE

US57777K1060

MXCT

Andere Sprachen

Filter